Workflow
Medical Care Facilities
icon
Search documents
How Is Universal Health Services’ Stock Performance Compared to Other Healthcare Providers?
Yahoo Finance· 2025-09-24 11:05
Company Overview - Universal Health Services, Inc. (UHS) has a market cap of $12.4 billion and operates various medical care facilities including acute care hospitals and behavioral health centers [1] - The company is categorized as a large-cap stock, reflecting its substantial size and influence in the medical care facilities industry [2] Financial Performance - UHS stock reached an all-time high of $243.25 on September 24, 2024, and is currently trading 20% below that peak [3] - Over the past three months, UHS stock has increased by 12.2%, outperforming the iShares U.S. Healthcare Providers ETF (IHF), which rose by 3.7% [3] - Year-to-date, UHS stock has climbed 8.5%, but has dropped 19.1% over the past 52 weeks, while IHF saw a 1.8% rise and a 14.7% decline over the same period [3] Technical Indicators - UHS has recently surpassed its 50-day and 200-day moving averages, indicating a potential uptrend [4] Market Position - UHS has underperformed compared to its peer Encompass Health Corporation (EHC), which experienced a 30.6% surge in 2025 and 37.3% returns over the past 52 weeks [5] Analyst Ratings - Among 20 analysts covering UHS stock, the consensus rating is a "Moderate Buy," with a mean price target of $217.75, suggesting an 11.8% upside potential from current price levels [6]
Is DaVita Stock Underperforming the Nasdaq?
Yahoo Finance· 2025-09-23 13:56
Company Overview - DaVita Inc. (DVA) is valued at a market cap of $9.4 billion and provides kidney dialysis services for patients with chronic kidney failure, including outpatient, hospital inpatient, and home-based hemodialysis services, as well as clinical laboratory services [1] - The company is classified as a "mid-cap stock" due to its market cap exceeding $2 billion, highlighting its size and influence in the medical care facilities industry [2] Financial Performance - In Q2, DaVita reported total revenue of $3.4 billion, a 6.1% year-over-year increase, with dialysis patient service revenues growing by 4.8% [5] - The adjusted EPS for the quarter was $2.95, reflecting a 47.5% increase from the previous quarter, driven by strong margin expansions [5] - However, operating cash flow declined by 59.4% year-over-year to $324 million, and free cash flow fell 76% year-over-year to $157 million, negatively impacting investor sentiment [5] Stock Performance - DaVita's stock has decreased 27% from its 52-week high of $179.60, with a 4.2% decline over the past three months, underperforming the Nasdaq Composite's 17.2% return [3][4] - Over the past 52 weeks, DVA has fallen 20%, significantly lagging behind the NASX's 27% increase during the same period [4] - Year-to-date, shares of DVA are down 12.3%, compared to NASX's 18% rise [4] Competitive Position - DaVita has underperformed compared to its rival, Fresenius Medical Care AG (FMS), which has seen a 26.7% increase over the past 52 weeks and a 13.5% rise year-to-date [6] - Analysts maintain a cautious outlook on DaVita, with a consensus rating of "Hold" and a mean price target of $153.57, suggesting a 17.1% premium to its current price levels [6]